Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Takeda Pharmaceutical Company Limited before investing.

In this article, we go over a few key elements for understanding Takeda Pharmaceutical Company Limited’s stock price such as:

• Takeda Pharmaceutical Company Limited’s current stock price and volume
• Why Takeda Pharmaceutical Company Limited’s stock price changed recently
• Upgrades and downgrades for TAK from analysts
• TAK’s stock price momentum as measured by its relative strength

About Takeda Pharmaceutical Company Limited (TAK)

Before we jump into Takeda Pharmaceutical Company Limited’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.

Want to learn more about Takeda Pharmaceutical Company Limited’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Takeda Pharmaceutical Company Limited.

Takeda Pharmaceutical Company Limited’s Stock Price as of Market Close

As of July 31, 2026, 1:01 PM, CST, Takeda Pharmaceutical Company Limited’s stock price was $17.115.

Takeda Pharmaceutical Company Limited is down 0.78% from its previous closing price of $17.250.

During the last market session, Takeda Pharmaceutical Company Limited’s stock traded between $16.932 and $17.190. Currently, there are approximately 9.94 million shares outstanding for Takeda Pharmaceutical Company Limited.

Takeda Pharmaceutical Company Limited’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Takeda Pharmaceutical Company Limited Stock Price History

Takeda Pharmaceutical Company Limited’s (TAK) price is currently up 6.77% so far this month.

During the month of July, Takeda Pharmaceutical Company Limited’s stock price has reached a high of $17.830 and a low of $15.905.

Over the last year, Takeda Pharmaceutical Company Limited has hit prices as high as $18.895 and as low as $12.990. Year to date, Takeda Pharmaceutical Company Limited’s stock is up 9.78%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Takeda Pharmaceutical Company Limited Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there were analysts who downgraded Takeda Pharmaceutical Company Limited’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Takeda Pharmaceutical Company Limited’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Takeda Pharmaceutical Company Limited’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Takeda Pharmaceutical Company Limited’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Takeda Pharmaceutical Company Limited (TAK) by visiting AAII Stock Evaluator.

Relative Price Strength of Takeda Pharmaceutical Company Limited

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, Takeda Pharmaceutical Company Limited has a weighted four-quarter relative price strength of 2.11%, which translates to a Momentum Score of 59 and is considered to be Average.

Want to learn more about how Takeda Pharmaceutical Company Limited is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Takeda Pharmaceutical Company Limited Stock Price: Bottom Line

As of July 31, 2026, Takeda Pharmaceutical Company Limited’s stock price is $17.115, which is down 0.78% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Takeda Pharmaceutical Company Limited stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.